CLOV Stock Overview
Provides medicare advantage plans in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Clover Health Investments, Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.59 |
| 52 Week High | US$4.87 |
| 52 Week Low | US$0.61 |
| Beta | 2.01 |
| 1 Month Change | -9.57% |
| 3 Month Change | 12.54% |
| 1 Year Change | 352.14% |
| 3 Year Change | 1.70% |
| 5 Year Change | n/a |
| Change since IPO | -64.80% |
Recent News & Updates
Recent updates
Clover Health: Expected Margin Contraction Is A Prelude To Exponential Growth
Mar 07We Think Clover Health Investments (NASDAQ:CLOV) Can Afford To Drive Business Growth
Feb 25
Clover Health: Undervalued Turnaround Play With Promising SaaS Potential
Jan 16Recent Earnings Disappointment Could Be An Ideal Buying Opportunity For Clover Health
Dec 21Clover Health: Buy The Dip, Reap The Rewards
Nov 18Clover Health Investments, Corp. (NASDAQ:CLOV) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 08Clover Health's Rally: The Payoff Of A Profitable Pivot
Nov 06There's Reason For Concern Over Clover Health Investments, Corp.'s (NASDAQ:CLOV) Massive 37% Price Jump
Oct 03Clover Health: Changing Business Model, Seeking Profitability
Oct 03Clover Health: A Profitable Future Ahead Fueled By AI And Star Rating Success
Aug 15Clover Health Investments, Corp. (NASDAQ:CLOV) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Aug 14Here's Why We're Watching Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Aug 06Clover Health Investments, Corp.'s (NASDAQ:CLOV) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jun 12Clover Health Investments, Corp.'s (NASDAQ:CLOV) 26% Dip In Price Shows Sentiment Is Matching Revenues
Apr 20Clover Health Investments, Corp. (NASDAQ:CLOV) Analysts Are Reducing Their Forecasts For This Year
Mar 16Will Clover Health Investments (NASDAQ:CLOV) Spend Its Cash Wisely?
Mar 06Clover Health: Its Luck May Have Ran Out
Feb 26Here's Why We're Not Too Worried About Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Nov 21We're Hopeful That Clover Health Investments (NASDAQ:CLOV) Will Use Its Cash Wisely
Jul 07Chamath Palihapitiya-linked Clover Health Investments trading near all-time low
Oct 14Shareholder Returns
| CLOV | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -3.5% | 0.4% | -1.7% |
| 1Y | 352.1% | -4.3% | 5.6% |
Return vs Industry: CLOV exceeded the US Healthcare industry which returned -4.3% over the past year.
Return vs Market: CLOV exceeded the US Market which returned 5.6% over the past year.
Price Volatility
| CLOV volatility | |
|---|---|
| CLOV Average Weekly Movement | 7.9% |
| Healthcare Industry Average Movement | 6.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CLOV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CLOV's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 570 | Andrew Toy | www.cloverhealth.com/en/ |
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through one segment: Insurance. It also offers Clover Assistant, a cloud-based software platform that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights about the patients they treat.
Clover Health Investments, Corp. Fundamentals Summary
| CLOV fundamental statistics | |
|---|---|
| Market cap | US$1.83b |
| Earnings (TTM) | -US$46.27m |
| Revenue (TTM) | US$1.37b |
1.3x
P/S Ratio-39.6x
P/E RatioIs CLOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLOV income statement (TTM) | |
|---|---|
| Revenue | US$1.37b |
| Cost of Revenue | US$1.01b |
| Gross Profit | US$364.34m |
| Other Expenses | US$410.60m |
| Earnings | -US$46.27m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | 26.58% |
| Net Profit Margin | -3.38% |
| Debt/Equity Ratio | 0% |
How did CLOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/30 07:14 |
| End of Day Share Price | 2025/03/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clover Health Investments, Corp. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Fischbeck | BofA Global Research |
| Richard Close | Canaccord Genuity |
| Jason Cassorla | Citigroup Inc |